BIRC5 and malignant colon neoplasm: On the other hand, aberrant expression of survivin has been shown to be involved in resistance to treatment in colon cancer [14], [70]–[74]; XIAP was also shown to be a target and play a role in drug resistance in colon cancer [75]–[79].